BlackRock Health Sciences Term Trust Stock: price and insider trades · United States · SEC (Form 4)

About BlackRock Health Sciences Term Trust

BlackRock Health Sciences Term Trust (ticker: BMEZ) is a U.S.-listed closed-end fund traded on the NYSE in the United States. It is organized as a diversified closed-end management investment company and was launched on January 29, 2020 by BlackRock, the global asset manager. For investors, BMEZ is best understood as a listed, actively managed health-care/health-sciences vehicle designed to deliver total return and income, with long-term capital appreciation as the primary economic driver. The fund’s core investment mandate is straightforward but broad. Under normal market conditions, BMEZ invests at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries, together with equity derivatives that provide exposure to that same universe. In practice, that means the portfolio can span major pharmaceuticals, biotechnology, medical devices, life sciences tools, diagnostics, health-care services, and other innovation-driven medical businesses. This breadth gives the fund diversified exposure to one of the most structurally attractive and research-intensive sectors in global equities. From a competitive standpoint, BMEZ benefits from BlackRock’s scale, distribution reach, and deep fundamental-equity capabilities. It is managed within BlackRock’s health sciences platform, which gives the fund access to specialist sector expertise rather than a generic multi-sector approach. That said, the vehicle remains subject to classic health-care risks: regulatory and reimbursement pressure, drug pricing scrutiny, binary clinical trial outcomes, patent cliffs, competitive disruption, and shifts in investor appetite for growth stocks. For that reason, BMEZ is more of a tactical sector allocation or income-oriented closed-end fund than a low-volatility defensive product. One of BMEZ’s key selling points is access. Rather than requiring investors to build a health-care portfolio stock by stock, the fund offers a single listed wrapper with professional security selection and active rebalancing. The portfolio is geographically diversified, but the fund is U.S.-based and listed on the NYSE, which is important for investors in Europe looking at American markets and dollar-denominated exposure. The underlying holdings typically include both U.S. and international names, reflecting the global nature of the health sciences industry. Recent headlines have centered on capital structure management. In 2025, BlackRock announced and completed a tender offer for up to 40% of BMEZ’s outstanding common shares, an important signal for closed-end fund investors because it addresses discount control and shareholder liquidity. Recent fund materials also show a meaningful allocation across pharmaceuticals, medical devices, biotechnology, and health-care services, reinforcing BMEZ’s role as a diversified, actively managed health-sciences income vehicle rather than a narrow single-theme fund.